Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: bucko who wrote (359)	11/30/1999 12:48:00 AM
From: Steven Rachbach	Respond to of 1127

We'll probably see some flavor of split at the BOD meeting following the approval of additional shares. What I'd like to see happen to many of the additional shares may be downright anathematic to many shareholders. I would like HGSI to use the runup in its stock price and its new found shares to acquire companies to further fuel its long-term growth. Sure the deals may be short-term dilutive, but I envision HGSI to be a dominant company in the genomics/pharmaceutical field and so acquisitions will be necessary along the way to achieve that dominance. For instance, earlier this year, HGSI partnered with a company that will make monoclonal antibodies to proteins that HGSI will derive from its functional genomics program. In the near future, with HGSI's stock "currency" at current levels, HGSI should spend some of its appreciating stock and acquire a company outright rather than just having a partnership deal with it.